171 related articles for article (PubMed ID: 22163167)
1. Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.
Colombo GL; Colangeli V; Di Biagio A; Di Matteo S; Viscoli C; Viale P
Clinicoecon Outcomes Res; 2011; 3():197-205. PubMed ID: 22163167
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy.
Rizzardini G; Bonfanti P; Carenzi L; Coen M; Orlando G; Di Matteo S; Colombo GL
Ther Clin Risk Manag; 2012; 8():377-84. PubMed ID: 23028230
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.
Colombo GL; Di Matteo S; Antinori A; Medaglia M; Murachelli S; Rizzardini G
Clinicoecon Outcomes Res; 2013 Oct; 5():489-96. PubMed ID: 24124383
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen.
Colombo GL; Di Matteo S; Maggiolo F
Clinicoecon Outcomes Res; 2013; 5():59-68. PubMed ID: 23430273
[TBL] [Abstract][Full Text] [Related]
5. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting.
Colombo GL; Castagna A; Di Matteo S; Galli L; Bruno G; Poli A; Salpietro S; Carbone A; Lazzarin A
Ther Clin Risk Manag; 2014; 10():9-15. PubMed ID: 24379676
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
8. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
[TBL] [Abstract][Full Text] [Related]
11. Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?
Marcellusi A; Viti R; Damele F; Cammà C; Taliani G; Mennini FS
Clin Drug Investig; 2016 Aug; 36(8):661-72. PubMed ID: 27234943
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US.
Juday T; Correll T; Anene A; Broder MS; Ortendahl J; Bentley T
Clinicoecon Outcomes Res; 2013; 5():437-45. PubMed ID: 24039438
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.
Bendavid E; Grant P; Talbot A; Owens DK; Zolopa A
AIDS; 2011 Jan; 25(2):211-20. PubMed ID: 21124202
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients.
Restelli U; Rizzardini G; Antinori A; Lazzarin A; Bonfanti M; Bonfanti P; Croce D
Ther Clin Risk Manag; 2017; 13():787-797. PubMed ID: 28721059
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.
Maggiolo F; Colombo GL; Di Matteo S; Bruno GM; Astuti N; Di Filippo E; Masini G; Bernardini C
Patient Relat Outcome Meas; 2015; 6():53-60. PubMed ID: 25733942
[TBL] [Abstract][Full Text] [Related]
18. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
Omeje I; Okwundu CI
Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
20. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
Brogan A; Mauskopf J; Talbird SE; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
